Posted inClinical Updates Wellness & Lifestyle
Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial
The REACH3 study confirms ruxolitinib's superiority over best available therapy in steroid-refractory/dependent chronic GVHD, demonstrating sustained efficacy, improved failure-free survival, and a manageable long-term safety profile over three years.